Scientific Reports · 2021 · 21 citations · 48 references
MedicinePharmacokineticsPharmacologyCardiac TransplantationPharmacogeneticsPharmacokinetic VariabilityCorticosteroid Use In TransplantationHeart TransplantationImmunosuppression ManagementPharmacogenomics In TransplantationTransplant PharmacokineticsTransplant PharmacologyGenetic PolymorphismsPatient Dose ReductionPharmacokinetics In Heart TransplantationTacrolimus ExposureTacrolimus PharmacogeneticsTacrolimus PharmacogenomicsTacrolimus PharmacokineticsTacrolimus Therapy
Abstract High inter-individual variability in tacrolimus clearance is attributed to genetic polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by non-genetic factors, continuous changes in tacrolimus-metabolizing capacity entail frequent dose-refinement for optimal immunosuppression. In heart transplant recipients, the contribution of patients’ CYP3A-status ( CYP3A5 genotype and CYP3A4 expression) to tacrolimus blood concentration and dose-requirement was evaluated in the early and late post-operative period. In low CYP3A4 expressers carrying CYP3A5*3/*3 , the dose-corrected tacrolimus level was significantly higher than in normal CYP3A4 expressers or in those with CYP3A5*1 . Modification of the initial tacrolimus dose was required for all patients: dose reduction by 20% for low CYP3A4 expressers, a 40% increase for normal expressers and a 2.4-fold increase for CYP3A5*1 carriers. The perioperative high-dose corticosteroid therapy was assumed to ameliorate the low initial tacrolimus-metabolizing capacity during the first month. The fluctuation of CYP3A4 expression and tacrolimus blood concentration (C 0 /D) was found to be associated with tapering and cessation of corticosteroid in CYP3A5 non-expressers, but not in those carrying CYP3A5*1 . Although monitoring of tacrolimus blood concentration cannot be omitted, assaying recipients’ CYP3A-status can guide optimization of the initial tacrolimus dose, and can facilitate personalized tacrolimus therapy during steroid withdrawal in the late post-operative period.
48
Haploview: analysis and visualization of LD and haplotype maps
Jeffrey C. Barrett, Ben Fry, Julian Maller et al. · Bioinformatics · 2004 · 14.7K citations · Full text
Daniel C. Chambers, Wida S. Cherikh, Michael O. Harhay et al. · The Journal of Heart and Lung Transplantation · 2019 · 1.3K citations · Full text
Medicine, Cardiology, Surgery +17
Kiran K. Khush, Wida S. Cherikh, Daniel C. Chambers et al. · The Journal of Heart and Lung Transplantation · 2019 · 934 citations
Medicine, Cardiology, Surgery +17
Human P-glycoprotein transports cyclosporin A and FK506.
Takashi Saeki, Kazumitsu Ueda, Yusuke Tanigawara et al. · Journal of Biological Chemistry · 1993 · 685 citations · Full text
Medicine, Biochemistry, Pharmacology +15